[Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
Dhainaut
J F
JF
Département de réanimation, hôpital Cochin, Paris, France.
Payen
D M
DM
Bernardin
G
G
Gérard
J L
JL
Martin
C
C
Perrotin
D
D
Regnier
B
B
D000465:Algorithms; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D006801:Humans; D009102:Multiple Organ Failure / Q000188:drug therapy* / Q000209:etiology*; D018579:Patient Selection; D011486:Protein C / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use*; D018570:Risk Assessment; D018805:Sepsis / Q000150:complications* / Q000188:drug therapy*; D012720:Severity of Illness Index
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated